

Drug Monograph

Drug/Drug **Lotemax (loteprednol etabonate) gel / ophthalmic**
Class: **corticosteroid**
Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Each gram of Lotemax gel contains 5 mg of loteprednol etabonate, as a sterile preserved ophthalmic gel.

Manufacturer: Bausch & Lomb Incorporated, Tampa, Florida 33637 USA

Indications: Lotemax gel is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

Costs: \$122.03 per 5 gram bottle of Lotemax 0.5% gel. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion into the state specific Preferred Drug List and is currently under solicitation.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Clinical Edit PDL

Type of PA Criteria: Increased Risk of ADE Preferred Agent
 Appropriate Indications Non-Preferred

Prepared By: Kathleen Wilbers, Pharm.D.
Date: February 7, 2013